This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,375.00 to support research on the role of the GPR37L1 receptor in chronic migraine. The funding will enable a research team at Florida Atlantic University, with a sub-award to the University of Florida, to conduct a comprehensive investigation into the involvement of GPR37L1 signaling in the neuropathology of...
This Project Grant award of $472,592 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to evaluate the potential of RGIA5474, a novel A9A10 nicotinic acetylcholine receptor (nAChR) antagonist, as a treatment for migraine. The research aims to assess RGIA5474's ability to alleviate migraine-related pain behaviors, neurochemical changes, and...
This $444,125 Project Grant, awarded on July 18, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of progesterone receptors in regulating the transition from episodic to chronic migraine. The key objectives are to: 1) Use mouse models to assess how modulating progesterone receptor signaling affects migraine...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", provides $620,278 to the University of Maryland, Baltimore to investigate the molecular basis for using sphingosine-1-phosphate receptor 1 (S1PR1) antagonists to treat the comorbid conditions of migraine and temporomandibular disorders (TMDs). The research aims to establish...
This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, awarded the University of Oregon a $301,172 project grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The purpose of this 3-year project is to develop scalable fabrication methods for high-density amorphous silicon carbide microelectrode arrays to enable chronic neural interfacing for recording neural activity in studies...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $475,475 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on the pathophysiology of morning migraine. The key objectives of this 2-year award are to: 1) Define the quantitative and qualitative profiles of complement and purinergic receptors and regulators...
The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $578,701 project grant to the University of California, Los Angeles (UCLA) on June 16, 2025. The goal of this 5-year project is to develop a near-infrared confocal squeezed light-field microscopy (SLIM) system capable of kilohertz volumetric imaging of neuronal action potentials in 3D. This technology is intended to...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $441,500 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Duquesne University of the Holy Spirit. The purpose of this 3-year grant, beginning September 2023, is to utilize laboratory data and computational 3-D modeling to analyze the role of the central amygdala in neuropathic pain. Specifically, the project aims to build a proof-of-concept 3-D...